针对甲型流感病毒的亚单位和 VLP 疫苗的研发进展。
Developments of subunit and VLP vaccines against influenza A virus.
机构信息
State Key Laboratory of Virology and Joint-Lab of Invertebrate Virology, Chinese Virus Resource and Bioinformatics Center, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China.
出版信息
Virol Sin. 2012 Jun;27(3):145-53. doi: 10.1007/s12250-012-3241-1. Epub 2012 Jun 9.
Abstract
Influenza virus is a continuous and severe global threat to mankind. The continuously re-emerging disease gives rise to thousands of deaths and enormous economic losses each year, which emphasizes the urgency and necessity to develop high-quality influenza vaccines in a safer, more efficient and economic way. The influenza subunit and VLP vaccines, taking the advantage of recombinant DNA technologies and expression system platforms, can be produced in such an ideal way. This review summarized the recent advancements in the research and development of influenza subunit and VLP vaccines based on the recombinant expression of hemagglutinin antigen (HA), neuraminidase antigen (NA), Matrix 2 protein (M2) and nucleocapsid protein (NP). It would help to get insight into the current stage of influenza vaccines, and suggest the future design and development of novel influenza vaccines.
摘要
流感病毒是对人类的持续且严重的全球性威胁。这种不断重现的疾病每年导致数千人死亡和巨大的经济损失，这强调了以更安全、更有效和更经济的方式开发高质量流感疫苗的紧迫性和必要性。流感亚单位和 VLP 疫苗利用重组 DNA 技术和表达系统平台，可以以这样一种理想的方式生产。本综述总结了基于血凝素抗原 (HA)、神经氨酸酶抗原 (NA)、基质 2 蛋白 (M2) 和核衣壳蛋白 (NP) 的重组表达的流感亚单位和 VLP 疫苗的最新研究进展。这有助于深入了解流感疫苗的现状，并为新型流感疫苗的设计和开发提供建议。
相似文献
1
Developments of subunit and VLP vaccines against influenza A virus.针对甲型流感病毒的亚单位和 VLP 疫苗的研发进展。
Virol Sin. 2012 Jun;27(3):145-53. doi: 10.1007/s12250-012-3241-1. Epub 2012 Jun 9.
2
Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines.利用 M2 融合蛋白制备流感病毒样颗粒用于单病毒成像和疫苗设计。
Vaccine. 2011 Sep 22;29(41):7163-72. doi: 10.1016/j.vaccine.2011.05.077. Epub 2011 Jun 7.
3
Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza.基于植物的针对H1N1和H5N1流感的重组亚基血凝素疫苗的快速生产
Hum Vaccin. 2011 Jan-Feb;7 Suppl:41-50. doi: 10.4161/hv.7.0.14561. Epub 2011 Jan 1.
4
A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1).一种新型鼻内病毒样颗粒（VLP）疫苗，旨在预防1918年大流行的甲型流感病毒（H1N1）。
Viral Immunol. 2007 Sep;20(3):441-52. doi: 10.1089/vim.2007.0027.
5
Influenza virus-like particle vaccines.流感病毒样颗粒疫苗。
Expert Rev Vaccines. 2009 Apr;8(4):435-45. doi: 10.1586/erv.09.8.
6
Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes.流感病毒样颗粒可以容纳多种亚型的血凝素，从而预防多种流感类型和亚型。
Vaccine. 2011 Aug 11;29(35):5911-8. doi: 10.1016/j.vaccine.2011.06.068. Epub 2011 Jun 30.
7
Research and development of universal influenza vaccines.通用流感疫苗的研发。
Microbes Infect. 2010 Apr;12(4):280-6. doi: 10.1016/j.micinf.2010.01.001. Epub 2010 Jan 15.
8
Progress on adenovirus-vectored universal influenza vaccines.腺病毒载体通用流感疫苗的研究进展。
Hum Vaccin Immunother. 2015;11(5):1209-22. doi: 10.1080/21645515.2015.1016674.
9
A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.一种缺乏糖蛋白基因并表达流感病毒血凝素和神经氨酸酶的有活力的重组弹状病毒是一种有效的流感疫苗。
J Virol. 2015 Mar;89(5):2820-30. doi: 10.1128/JVI.03246-14. Epub 2014 Dec 24.
10
Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge.杆状病毒生产的流感病毒样颗粒在哺乳动物细胞中保护小鼠免受致死性流感病毒的攻击。
Viral Immunol. 2011 Aug;24(4):311-9. doi: 10.1089/vim.2011.0016.
引用本文的文献
1
Lentinan-functionalized PBAE-G-nanodiamonds as an adjuvant to induce cGAS-STING pathway-mediated macrophage activation and immune enhancement.香菇多糖功能化的聚（β-氨基酯）-G-纳米金刚石作为佐剂诱导cGAS-STING途径介导的巨噬细胞活化和免疫增强。
J Pharm Anal. 2024 Dec;14(12):100922. doi: 10.1016/j.jpha.2023.12.012. Epub 2023 Dec 22.
2
Outlining recent updates on influenza therapeutics and vaccines: A comprehensive review.概述流感治疗方法和疫苗的最新进展：全面综述。
Vaccine X. 2024 Jan 30;17:100452. doi: 10.1016/j.jvacx.2024.100452. eCollection 2024 Mar.
3
A subunit vaccine candidate based on the Spike protein of SARS-CoV-2 prevents infectious virus shedding in cats.基于 SARS-CoV-2 刺突蛋白的亚单位疫苗候选物可防止猫体内的感染性病毒脱落。
Res Vet Sci. 2022 Nov;148:52-64. doi: 10.1016/j.rvsc.2022.05.003. Epub 2022 May 29.
4
Solutions against emerging infectious and noninfectious human diseases through the application of baculovirus technologies.通过杆状病毒技术的应用来解决新发的感染性和非感染性人类疾病。
Appl Microbiol Biotechnol. 2021 Nov;105(21-22):8195-8226. doi: 10.1007/s00253-021-11615-1. Epub 2021 Oct 7.
5
Methodical Design of Viral Vaccines Based on Avant-Garde Nanocarriers: A Multi-Domain Narrative Review.基于前沿纳米载体的病毒疫苗的系统设计：多领域叙述性综述
Biomedicines. 2021 May 6;9(5):520. doi: 10.3390/biomedicines9050520.
6
Vaccine development and therapeutic design for 2019-nCoV/SARS-CoV-2: Challenges and chances.2019-nCoV/SARS-CoV-2 的疫苗研发和治疗设计：挑战与机遇。
J Cell Physiol. 2020 Dec;235(12):9098-9109. doi: 10.1002/jcp.29771. Epub 2020 Jun 18.
7
Coronavirus Pandemic-Therapy and Vaccines.冠状病毒大流行——治疗方法与疫苗
Biomedicines. 2020 May 3;8(5):109. doi: 10.3390/biomedicines8050109.
8
Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses.针对新兴致病性人类冠状病毒的亚单位疫苗
Front Microbiol. 2020 Feb 28;11:298. doi: 10.3389/fmicb.2020.00298. eCollection 2020.
9
Plasmid DNA-based Alphavirus Vaccines.基于质粒DNA的甲病毒疫苗。
Vaccines (Basel). 2019 Mar 8;7(1):29. doi: 10.3390/vaccines7010029.
10
Replicon RNA Viral Vectors as Vaccines.复制子RNA病毒载体作为疫苗
Vaccines (Basel). 2016 Nov 7;4(4):39. doi: 10.3390/vaccines4040039.
本文引用的文献
1
H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.H5N1 病毒样颗粒疫苗诱导产生交叉反应性中和抗体，这些抗体优先与人流感病毒血凝素的寡聚体形式结合。
J Virol. 2011 Nov;85(21):10945-54. doi: 10.1128/JVI.05406-11. Epub 2011 Aug 24.
2
Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico.在墨西哥进行的一项盲法、随机、安慰剂对照试验中评估了一种类似病毒颗粒的大流行性流感 A（H1N1）2009 疫苗在成人中的安全性和免疫原性。
Vaccine. 2011 Oct 13;29(44):7826-34. doi: 10.1016/j.vaccine.2011.07.099. Epub 2011 Aug 2.
3
Influenza virus-like particles as a new tool for vaccine immunogenicity testing: validation of a neuraminidase neutralizing antibody assay.流感病毒样颗粒作为疫苗免疫原性测试的新工具：神经氨酸酶中和抗体测定的验证。
J Virol Methods. 2011 May;173(2):364-73. doi: 10.1016/j.jviromet.2011.03.011. Epub 2011 Mar 16.
4
Virus-like particles in vaccine development.疫苗开发中的病毒样颗粒。
Expert Rev Vaccines. 2010 Oct;9(10):1149-76. doi: 10.1586/erv.10.115.
5
Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin.稳定三聚体可溶性流感血凝素的增强免疫原性。
PLoS One. 2010 Sep 1;5(9):e12466. doi: 10.1371/journal.pone.0012466.
6
Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses.人类抗体揭示了一个保护性表位，该表位在人类和非人类甲型流感病毒中高度保守。
Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12658-63. doi: 10.1073/pnas.0911806107. Epub 2010 Jul 1.
7
Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus.哺乳动物表达病毒样颗粒以高度模拟真实流感病毒。
PLoS One. 2010 Mar 22;5(3):e9784. doi: 10.1371/journal.pone.0009784.
8
Influenza neuraminidase as a vaccine antigen.流感神经氨酸酶作为一种疫苗抗原。
Curr Top Microbiol Immunol. 2009;333:227-41. doi: 10.1007/978-3-540-92165-3_12.
9
Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus.针对禽流感H5N1 A/越南/1203/2004流感病毒的重组流感H5血凝素疫苗在小鼠体内的制备、表征及免疫原性
Vaccine. 2009 Oct 19;27(44):6234-8. doi: 10.1016/j.vaccine.2009.07.107. Epub 2009 Aug 15.
10
Emergence and pandemic potential of swine-origin H1N1 influenza virus.猪源H1N1流感病毒的出现及大流行潜力
Nature. 2009 Jun 18;459(7249):931-9. doi: 10.1038/nature08157.
Zotero 插件